On
Chemical Pathology Research
Chemical pathology is devoted to the measurement of the chemicals, hormones and metabolites that make life possible. Pathology is responsible for the study of all forms of disease, so the activities of our department are extremely broad and diverse. Our research encompasses many disorders which can be classified in terms of the organs or age-groups that they affect, but there is an understandable emphasis on those conditions that cause the greatest amount of death and disability in Australia at the moment.
Our Key Achievements
- Our department has led the implementation of strategies to address the most common potentially fatal genetic disorder, Familial Hypercholesterolaemia.
- Our department has led the implementation strategies to manage the first new independent risk factor for atherosclerotic CVD discovered this century, lipoproptein (a).
- Our department is at the forefront of innovations in personalized medicine involving trials of small interfering RNA therapies. These are based on Mendelian Randomization studies which have identified ANGPTL3, APO C3 and APO (a) as therapeutic targets. This will reduce the risk of CVD and acute pancreatitis in selected patients.
Our Research Team
| Kerry Kearins | Clinical Trial Coordinator |
| Collin Tran | Research Scientist |
Our Publications
2021
| Bulsara C, Brett T, Radford J, et al. Awareness of familial hypercholesterolaemia in Australian primary care: A qualitative descriptive study. Australian journal of general practice 2021;50:634-40. |
| Clifton P, Sullivan D, Baker J, et al. ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia. Circulation 2021;144:A10357-A. |
| Januszewski AS, Chen D, Scott RS, et al. Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific reports 2021;11:1-12. |
| Lin H-M, Mak B, Yeung N, et al. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine 2021;72:103625. |
| Nestel PJ, Sullivan DR, Mori TA. Dietary management of cardiovascular risk including type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 2021;28:134-41. |
| Ong K-L, Wu L, Januszewski AS, et al. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diabetes and Vascular Disease Research 2021;18:14791641211032547. |
| Pang J, Sullivan DR, Hare DL, et al. Gaps in the care of familial hypercholesterolaemia in Australia: first report from the National registry. Heart, Lung and Circulation 2021;30:372-9. |
| Spinks C, Watts GF, Pang J, Brett T, Sullivan DR. Genetic testing for familial hypercholesterolaemia: A test for the family. Medicine Today 2021;22. |
| Watts GF, Sullivan DR, Hare DL, et al. Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. Internal medicine journal 2021;51:769-79. |
| Watts GF, Sullivan DR, Hare DL, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart, Lung and Circulation 2021;30:324-49. |
| Watts GF, Sullivan DR, Hare DL, et al. Synopsis of an Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia: an Australian Perspective. American Journal of Preventive Cardiology 2021:100151. |
| Zhen XM, Lee KL, Sullivan D, Acharya S. New diagnosis of diabetes and severe hyperlipidemia at 3 months postpartum presenting as florid diabetic retinopathy and eruptive xanthomas. Journal of Obstetrics and Gynaecology Research 2021;Published ahead of print. |
| Cao, J., Waldman, B., O'Connell, R., Sullivan, D., Scott, R., Aryal, N., Gebski, V., Marschner, I., Taskinen, M., Simes, R., McGill, N., Jenkins, A., Keech, A. (2020). Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes, Obesity and Metabolism, 22(8), 1388-1396. |
| Foote, C., Hockham, C., Sukkar, L., Campain, A., Kang, A., Young, T., Cass, A., Chow, C., Comino, E., Gallagher, M., Jan, S., Pollock, C., Sullivan, D., Wong, G., et al (2020). Examining outcomes in chronic disease in the 45 and up study (the EXTEnD45 study): Protocol for an Australian linked cohort study. JMIR Research Protocols, 9(4), 1-11. |
| Hilvo, M., Meikle, P., Pedersen, E., Tell, G., Dhar, I., Brenner, H., Schottker, B., Laaperi, M., Kauhanen, D., Koistinen, K., Sullivan, D., Simes, R., et al (2020). Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. European Heart Journal, 41(3), 371-380. |
| Koren, M., Jones, P., Robinson, J., Sullivan, D., Cho, L., Hucko, T., Lopez, A., Fleishman, A., Somaratne, R., Stroes, E. (2020). A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. Cardiology and Therapy, 9(2), 447-465. |
| Pang, J., Sullivan, D., Brett, T., Kostner, K., Hare, D., Watts, G. (2020). Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application. Heart, Lung, and Circulation, 29(4), 619-633. |
| Sukkar, L., Kang, A., Hockham, C., Young, T., Jun, M., Foote, C., Pecoits-Filho, R., Neuen, B., Rogers, K., Pollock, C., Sullivan, D., Wong, G., Knight, J., Gallagher, M., et al (2020). Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study. Diabetes Care, 43(5), 982-990. |
| Watts, G., Gidding, S., Mata, P., Pang, J., Sullivan, D., Yamashita, S., Raal, F., Santos, R., Ray, K. (2020). Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nature Reviews Cardiology, 17(6), 360-377. |
| Zhang, H., Rogers, K., Sukkar, L., Jun, M., Kang, A., Young, T., Campain, A., Cass, A., Chow, C., Comino, E., Gallagher, M., Pollock, C., Sullivan, D., Wong, G., et al (2020). Prevalence, incidence and risk factors of diabetes in Australian adults aged ?45 years: A cohort study using linked routinely-collected data. Journal of Clinical and Translational Endocrinology, 22, 100240. |
| Carr, S., Hooper, A., Sullivan, D., Burnett, J. (2019). Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology, 51(2), 148-154 |
| Jayawardana, K., Mundra, P., Giles, C., Barlow, C., Nestel, P., Barnes, E., Kirby, A., Thompson, P., Sullivan, D., Alshehry, Z., Marschner, I., Simes, R., et al (2019). Changes in plasma lipids predict pravastatin efficacy in secondary prevention. JCI Insight, 4(13), 1-13. |
| Kott, K., Vernon, S., Hansen, T., Yu, C., Bubb, K., Coffey, S., Sullivan, D., Yang, J., O'Sullivan, J., Chow, C., Patel, S., Chong, J., Celermajer, D., Kritharides, L., Grieve, S., Figtree, G. (2019). Biobanking for discovery of novel cardiovascular biomarkers using imaging-quantified disease burden: protocol for the longitudinal, prospective, BioHEART-CT cohort study. BMJ Open, 9(9), 1-9 |
| Sivashanmugarajah, A., Fulcher, J., Sullivan, D., Elam, M., Jenkins, A., Keech, A. (2019). Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects. Internal Medicine Journal, 49(9), 1081-1091. |
| Ward, N., Kostner, K., Sullivan, D., Nestel, P., Watts, G. (2019). Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far? Journal of Clinical Medicine, 8(12), 1-23. |